Table 1.
Distribution of prognostic phenotypes in 899 patients from the POSH cohort according to outcome
| Outcome | Number | DDFSa | ER statusb | Tumour gradeb | Diameter (cM) | pN stageb | ||||
| Negative | Positive | 1 | 2 | 3 | 1 | 0 | ||||
| Deceased | 102 | 1.48 (0.00 to 4.77) | 53 (53.0) | 47 (47.0) | 2 (2.0) | 19 (19.2) | 78 (78.8) | 3.67 | 70 (76.9) | 21 (23.1) |
| Distant relapse | 55 | 1.90 (0.00 to 4.62) | 18 (32.7) | 37 (67.3) | 2 (3.8) | 18 (34.0) | 33 (62.0) | 3.00 | 38 (74.5) | 13 (25.5) |
| Disease free | 742 | 2.61 (0.05 to 6.69) | 202 (27.6) | 531 (72.4) | 60 (8.2) | 269 (36.8) | 402 (55.0) | 2.58 | 352 (48.4) | 376 (51.6) |
| Total | 899 | 2.44 (0.00 to 6.69) | 273 (30.7) | 615 (69.3) | 64 (7.2) | 306 (34.7) | 513 (58.1) | 2.72 | 460 (52.9) | 410 (47.1) |
aDistant disease free survival times in years and (range). bNumbers outside parenthesis represent counts while those inside are percentages of the total number in each outcome group. DDFS, distant disease-free survival; ER, ostrogen receptor; pN, pathological nodal; POSH, Prospective study of Outcomes in Sporadic versus Hereditary breast cancer.